Ipsen Announces At American Society of Clinical Oncology GI That ELECT® Clinical Trial Of Somatuline® In The Control Of Symptoms In GEP-NET1 Patients With Carcinoid Syndrome Met Its Primary Endpoint
Published: Jan 17, 2014
PARIS--(BUSINESS WIRE)--Regulatory News:
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced that the results of the ELECT® phase III clinical study with Somatuline® Autogel® / Somatuline® Depot® (lanreotide) Injection (hereafter referred to as Somatuline®) will be presented on Friday 17 January 2014 at the Gastrointestinal Cancers Symposium, San Francisco, CA, USA.
Help employers find you! Check out all the jobs and post your resume.